Navigation Links
NJHA: Public Deserves Full Disclosure of Horizon Conversion Plan
Date:9/11/2008

PRINCETON, N.J., Sept. 11 /PRNewswire-USNewswire/ -- The New Jersey Hospital Association today called for greater transparency of Horizon Blue Cross/Blue Shield's application to become a for-profit company.

"There is far too much at stake for the people of New Jersey to have this process proceed with key information shielded from the public," said NJHA President and CEO Betsy Ryan. "New Jersey residents are rightfully concerned about the high cost of health insurance and access to coverage. They deserve a full and open airing of this important issue."

NJHA's appeal comes after its request for more information, made under the state's Open Public Records Act, was denied Monday by the state Attorney General's office. The state's release of additional information yesterday shed little light on critical business analyses, financial projections and other information that would help determine whether the conversion plan truly is in the public interest. These critical documents - and much more - were made publicly available in other states where conversions were proposed, including Maryland, Washington and Kansas. Much of the information released yesterday by the Department of Banking and Insurance has been available on the Horizon Web site.

Horizon is the state's largest insurer, covering 46 percent of New Jersey's insured residents - including the State of New Jersey's workforce. If the state approves its request to switch from a nonprofit to for-profit company, the state stands to benefit from the interest dollars generated by $1 billion or more in public assets that would be placed in a public trust. Annual interest from those dollars could be used to fund state programs, presumably for healthcare.

However, said Ryan, such a conversion plan also holds tremendous implications for the public. Horizon is New Jersey's insurer of last resort and covers a great deal of New Jersey's Medicaid beneficiaries. Key questions demand answers, she sa
'/>"/>

SOURCE New Jersey Hospital Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. NJHA: State Report Provides Thorough Examination of Hospital Fiscal Woes
2. NJHA: State Faces Access-to-Care Crisis
3. NJHA: No Hospital Safe from States $143 Million Cut
4. Mailman School of Public Health study examines link between racial discrimination and substance use
5. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
6. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
7. Open access to health research publications
8. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
9. PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors
10. Weiner Public News First Media Team at National Press Club 5K
11. ComPsych(R) Corp. Announces Health at Work(SM) Award Winners: Sprint, Erie Insurance, City of Naperville and Green Hills Public Library
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8